K

Kopran Ltd

Q2 FY27Pharmaceuticals & Biotechnology

Kopran Q2 Results 2026: PAT ₹4 Cr (turned profitable)

Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹211Cr
+79.2% YoY
+37.2% QoQ
Net profit
₹4Cr
Turned profitable YoY
−34.5% QoQ
Margin
7.29%
+11.8 pp YoY
−3 pp QoQ

Kopran Ltd Q2 FY27 key numbers

Revenue
Revenue from Operations for Q2 FY 2026-27: Rs. 21,126 lakhs.

As stated in Kopran Ltd's Q2 FY27 investor presentation · published 3 Nov 2026. Reported figures, not investment advice.

Based on Kopran Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹242
Market cap₹1.2K Cr
P/E46.8

The short version

Revenue from Operations for Q2 FY 2026-27: Rs. 21,126 lakhs (Page 5). EBITDA for Q2 2026-27: Rs. 1,822 Lakhs, up from Rs. 299 Lakhs in Q2 2025-26 (YoY increase).

From Kopran Ltd's Q2 FY27 earnings-call transcript · updated 3 Nov 2026.

How did Kopran's revenue grow in the September 2026 quarter?

- Revenue from Operations for Q2 FY 2026-27: Rs. 21,126 lakhs (Page 5) - Revenue from Operations for Q2 FY 2025-26: Rs. 11,791 lakhs (Page 5) - Year-on-year increase in Q2 revenue: Rs. 9,335 lakhs (~79% increase) Summary: Q2 revenue grew from Rs. 11,791 lakhs in FY 2025-26 to Rs.

What happened to Kopran's margins in Q2 FY27?

EBITDA for Q2 2026-27: Rs. 1,822 Lakhs, up from Rs. 299 Lakhs in Q2 2025-26 (YoY increase).

Locked: what Kopran Ltd said on margins

Also locked on this page: fundraising, order book

Free account, 30 seconds. No card needed.

What capex is Kopran planning?

- Focus on capacity expansion is highlighted as a strategic imperative (Page 15). - Emphasis on process improvements and atomization of packing lines in formulations without quantification (Page 15). Overall, the presentation notes capacity expansion and facility development (Panoli, Gujarat) as strategic priorities.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Kopran raising money or cutting debt?

Borrowings (Rs. in Lakhs) increased from 15,269 in FY 2025-26 to 20,837 in HY SEP-2026, indicating a rise…

Locked: what Kopran Ltd said on fundraising

Also locked on this page: margins, order book

Free account, 30 seconds. No card needed.

How big is Kopran's order book?

See what Kopran Ltd said on order book & pipeline — free account, 30 seconds.

Kopran Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Kopran Ltd Q2 FY27 results — key figures

Kopran Ltd Q2 FY27 reported results vs year-ago quarter, ₹ crore
₹ CrQ2 FY27
Revenue211
Operating profit (EBITDA)15
Operating margin7.3%
Profit before tax6
Net profit (PAT)4
EPS (₹)0.91

Source: Kopran Ltd's results filing to NSE (consolidated), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹211 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

More Q2 FY27 results in Pharmaceuticals & Biotechnology

All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings

Others in Pharmaceuticals & Biotechnology this season

  • Vineet Laborator (Q2 FY27)

    Year-on-year change: Decrease of approximately INR 323.65 lakh or about 18.58% decline . Key results statement takeaways from Vineet Laboratories Ltd's Q2 FY27

  • Balaxi Pharma (Q2 FY27)

    34.1% increase (from Rs. Key results statement takeaways from Balaxi Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Alkem Lab (Q2 FY27)

    Total Revenue from Operations in Q2 FY27: ₹45,520 million, up 13.8% YoY. Key investor presentation takeaways from Alkem Laboratories Ltd's Q2 FY27 investor pres

  • Caplin Point Laboratories Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹629.84 crore, up 17.9% YoY (compared to ₹534.04 crore in Q2 FY26). Key investor presentation takeaways from Caplin Point Labor

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Kopran Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Kopran Ltd Q2 FY27 results?

Revenue from Operations for Q2 FY 2026-27: Rs. 21,126 lakhs (Page 5). EBITDA for Q2 2026-27: Rs. 1,822 Lakhs, up from Rs. 299 Lakhs in Q2 2025-26 (YoY increase).

What is Kopran Ltd share price analysis?

Kopran Ltd currently shows a neutral. The stock trades at a P/E of 46.8 with a market cap of ₹1,171 Cr. Investors should review the full earnings analysis for detailed insights.

Is Kopran Ltd planning capital expenditure?

Focus on capacity expansion is highlighted as a strategic imperative (Page 15). - Emphasis on process improvements and atomization of packing lines in formulations without quantification (Page 15).

Keep Kopran Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.